Advancements in chemotherapy and immunotherapy have improved multiple myeloma survival rates, with 5-year relative survival increasing from 37.7% to 60.3% between 2000-2004 and 2015-2019. Treatment ...

The Phase 3 MajesTEC 3 trial showed that teclistamab plus daratumumab reduced the risk of progression or death by 83% and ...

Teclistamab-cqyv plus subcutaneous daratumumab significantly improved OS and PFS in relapsed/refractory multiple myeloma compared to standard regimens, reducing death risk by 54%. The combination ...

The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus daratumumab (Darzalex, Johnson & Johnson/Janssen) reduced the risk for ...

The complete response or better rate was 81.1% with the combination versus 31.1% in the control arm, while patients treated with the combination were more likely to test negative for minimal residual ...

The FDA has awarded its latest national priority voucher to Johnson & Johnson’s Tecvayli (teclistamab-cqyv) in combination with daratumumab for the treatment of relapsed or refractory multiple myeloma ...

ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling 'unprecedented.' Major pharmaceutical developers ...

Johnson & Johnson’s Tecvayli (teclistamab-cqyv), used in combination with daratumumab to treat relapsed or refractory multiple myeloma, has received FDA’s latest national priority voucher, becoming ...